262 related articles for article (PubMed ID: 33185628)
21. [Lambert-Eaton Myasthenic Syndrome].
Matsuo H
Brain Nerve; 2024 May; 76(5):630-634. PubMed ID: 38741506
[TBL] [Abstract][Full Text] [Related]
22. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Sanders DB
Ann N Y Acad Sci; 1998 May; 841():811-6. PubMed ID: 9668334
[No Abstract] [Full Text] [Related]
23. Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J; Mills KR
Muscle Nerve; 1998 Sep; 21(9):1196-8. PubMed ID: 9703446
[TBL] [Abstract][Full Text] [Related]
24. Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.
Meriney SD; Tarr TB; Ojala KS; Wu M; Li Y; Lacomis D; Garcia-Ocaña A; Liang M; Valdomir G; Wipf P
Ann N Y Acad Sci; 2018 Jan; 1412(1):73-81. PubMed ID: 29125190
[TBL] [Abstract][Full Text] [Related]
25. A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs.
Ojala KS; Ginebaugh SP; Wu M; Miller EW; Ortiz G; Covarrubias M; Meriney SD
J Biol Chem; 2021; 296():100302. PubMed ID: 33465376
[TBL] [Abstract][Full Text] [Related]
26. [Autoantibody against the presynaptic P/Q-type voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome].
Sakai W; Nakane S; Matsuo H
Brain Nerve; 2013 Apr; 65(4):441-8. PubMed ID: 23568992
[TBL] [Abstract][Full Text] [Related]
27. GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome.
Shimizu F; Takeshita Y; Sano Y; Hamamoto Y; Shiraishi H; Sato T; Yoshimura S; Maeda T; Fujikawa S; Nishihara H; Kitanosono H; Tsujino A; Motomura M; Kanda T
Brain; 2019 Aug; 142(8):2253-2264. PubMed ID: 31236596
[TBL] [Abstract][Full Text] [Related]
28. Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J
Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of Lambert-Eaton myasthenic syndrome in a small cell lung cancer patient using 3,4-diaminopyridine: A case report.
Hyun JW; Kim SH; Jeong IH; Kim HT; Kim HJ
Oncol Lett; 2016 Mar; 11(3):1933-1935. PubMed ID: 26998103
[TBL] [Abstract][Full Text] [Related]
30. Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine.
Chan KY; Chang RS; Lau VW; Chan ML; Lai T
Ann Palliat Med; 2016 Oct; 5(4):311-314. PubMed ID: 27506750
[TBL] [Abstract][Full Text] [Related]
31. Amifampridine Phosphate (Firdapse) Is Effective in a Confirmatory Phase 3 Clinical Trial in LEMS.
Shieh P; Sharma K; Kohrman B; Oh SJ
J Clin Neuromuscul Dis; 2019 Mar; 20(3):111-119. PubMed ID: 30801481
[TBL] [Abstract][Full Text] [Related]
32. The European Lambert-Eaton Myasthenic Syndrome Registry: Long-Term Outcomes Following Symptomatic Treatment.
Meisel A; Sieb JP; Le Masson G; Postila V; Sacconi S
Neurol Ther; 2022 Sep; 11(3):1071-1083. PubMed ID: 35511347
[TBL] [Abstract][Full Text] [Related]
33. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
Titulaer MJ; Lang B; Verschuuren JJ
Lancet Neurol; 2011 Dec; 10(12):1098-107. PubMed ID: 22094130
[TBL] [Abstract][Full Text] [Related]
34. [Lambert-Eaton myasthenic syndrome].
Motomura M; Fukuda T
Brain Nerve; 2011 Jul; 63(7):745-54. PubMed ID: 21747145
[TBL] [Abstract][Full Text] [Related]
35. Neurogenic bladder in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.
Satoh K; Motomura M; Suzu H; Nakao Y; Fujimoto T; Fukuda T; Nakane S; Nakamura T; Eguchi K
J Neurol Sci; 2001 Jan; 183(1):1-4. PubMed ID: 11166786
[TBL] [Abstract][Full Text] [Related]
36. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.
Lundh H; Nilsson O; Rosén I; Johansson S
Acta Neurol Scand; 1993 Aug; 88(2):136-40. PubMed ID: 8213058
[TBL] [Abstract][Full Text] [Related]
37. Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis.
Takamori M
J Neuroimmunol; 2008 Sep; 201-202():145-52. PubMed ID: 18653248
[TBL] [Abstract][Full Text] [Related]
38. Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.
Flink MT; Atchison WD
J Bioenerg Biomembr; 2003 Dec; 35(6):697-718. PubMed ID: 15000529
[TBL] [Abstract][Full Text] [Related]
39. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
Sanders DB; Massey JM; Sanders LL; Edwards LJ
Neurology; 2000 Feb; 54(3):603-7. PubMed ID: 10680790
[TBL] [Abstract][Full Text] [Related]
40. Lambert-Eaton myasthenic syndrome during anesthesia: a report of 37 patients.
Weingarten TN; Araka CN; Mogensen ME; Sorenson JP; Marienau ME; Watson JC; Sprung J
J Clin Anesth; 2014 Dec; 26(8):648-53. PubMed ID: 25468580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
